Summit Therapeutics Inc.
A clinical-stage biopharmaceutical company founded in 2003 in Oxford, England, that develops new medicines for serious diseases — starting with antibiotics and later shifting its focus to cancer treatments such as the lung-cancer drug ivonescimab. It went through a string of odd early names, including CobraDragon and Vastox, before settling on "Summit," a nod to reaching the peak of healthcare. Today it is listed on Nasdaq and runs offices in Miami, California, and the UK.
Sponsored American Depositary Shares (ADS)
Granted 14.25M · Bought 4.28M
Granted 14.25M · Bought 4.28M
Bought 533.6K
Granted 53.4K · Bought 50.0K
Granted 26.7K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Duggan Robert WCo-Chief Executive Officer, Director, 10% owner · 7 transactions | — | 1.76B | 14.25M | 4.28M | — |
| Zanganeh MahkamCo-Chief Executive Officer, Director, 10% owner · 7 transactions | +3.1% | 610.02M | 14.25M | 4.28M | — |
| Xia YuDirector · 1 transaction | +48.9% | 32.06M | — | 533.6K | — |
| Soni Manmeet SinghCOO and CFO, Director · 3 transactions | +2.6% | 3.10M | 53.4K | 50.0K | — |
| Anand BhaskarChief Accounting Officer · 1 transaction | +21.6% | 159.8K | 26.7K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: +9.13M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.